Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)Company announcement No. 41 / 2026
- Imricor Medical Systems, Inc.Imricor Supports HRS Call for Enhanced Radiation Protection and Urges a Future Beyond Radiation ExposureMINNEAPOLIS, August 24, 2026--Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), the pioneer in the interventional magnetic resonance (iMR) field, welcomed the Heart Rhythm Society’s call for the urgent and immediate adoption of enhanced radiation-protection measures for clinicians and staff working in fluoroscopy-based procedure environments.1
- Kaplan Fox & Kilsheimer LLPKaplan Fox Reminds Hims & Hers Health, Inc. (HIMS) Investors of an Investigation into Potential Securities Law ViolationsKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing...
- BrainStorm Cell Therapeutics Inc.BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel SessionsExecutive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models. Pitts to moderate expert sessions on Translational Pharmaceutical Innovation and the Emerging...
- The Vitamin ShoppeThe Vitamin Shoppe Promotes Jack Gayton to Senior Vice President, MerchandisingMerchandising leader to advance The Vitamin Shoppe's growth strategy through product innovation, differentiated assortments, and strategic brand partnerships — The Vitamin Shoppe®, a leading specialty retailer of health and wellness products,...
- Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic InnovationU.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration with Neurothera Labs Inc. as the FDA introduces a dedicated regulatory structure for psychedelic drug development, including MDMA
- Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapyLiminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
- Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
- Elicio Therapeutics Inc.Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare ConferenceElicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.
- 74% of Healthcare Organizations Rate Their Patient Data Quality as Mixed or Poor, New Clinical Architecture Report FindsCARMEL, Ind., August 24, 2026--New report reveals a growing healthcare data trust gap, with poor-quality patient data creating challenges for interoperability and care.
- QurAlis to Participate in Upcoming Investor Conferences in SeptemberCAMBRIDGE, Mass., August 24, 2026--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will participate at the following investor conferences in September. Management will also participate in one-on-one investor meetings.
- PCB TechnologiesPCB Technologies Announces Winning of a USD 65 Million Tender for the Supply of Medical PCB Assembly Products in 2027-2028PCB Technologies (TASE: PCBT), a global leader in advanced electronic and PCB manufacturing solutions, is pleased to announce that on August 23, 2026, it was awarded a tender for the supply of electronic packaging products in 2027-2028...